BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20041350)

  • 1. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
    Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
    Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    Cancer Biol Ther; 2010 Jul; 10(1):99-107. PubMed ID: 20495354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
    Schwarz RE; Konduri S; Awasthi N; Cafasso D; Schwarz MA
    Surgery; 2009 Aug; 146(2):241-9. PubMed ID: 19628080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation.
    Schwarz RE; Awasthi N; Konduri S; Caldwell L; Cafasso D; Schwarz MA
    Cancer Biol Ther; 2010 Apr; 9(8):632-9. PubMed ID: 20212356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
    Awasthi N; Schwarz MA; Schwarz RE
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II.
    Schwarz RE; Schwarz MA
    J Surg Res; 2004 Jul; 120(1):64-72. PubMed ID: 15172191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
    Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
    Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Hinz S; Brekken RA; Schwarz MA; Schwarz RE
    Cancer Lett; 2015 Mar; 358(1):59-66. PubMed ID: 25527450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Schwarz MA; Schwarz RE
    Mol Cancer Ther; 2014 May; 13(5):1032-43. PubMed ID: 24608575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice.
    Solorzano CC; Hwang R; Baker CH; Bucana CD; Pisters PW; Evans DB; Killion JJ; Fidler IJ
    Clin Cancer Res; 2003 May; 9(5):1858-67. PubMed ID: 12738744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
    Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
    Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
    Awasthi N; Kirane A; Schwarz MA; Toombs JE; Brekken RA; Schwarz RE
    BMC Cancer; 2011 Jan; 11():15. PubMed ID: 21226944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
    Van Buren G; Ramanathan RK; Krasinskas AM; Smith RP; Abood GJ; Bahary N; Lembersky BC; Shuai Y; Potter DM; Bartlett DL; Zureikat AH; Zeh HJ; Moser AJ
    Ann Surg Oncol; 2013 Nov; 20(12):3787-93. PubMed ID: 23904005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.